NewAmsterdam Pharma Company NV held its 2025 annual general meeting of shareholders on June 4, 2025. The shareholders approved the adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2024. The discharge from liability for the company's directors with respect to the performance of their duties during the fiscal year 2024 was also approved. The appointment of and instruction to Deloitte Accounts B.V. as the external independent auditor for the audit of the company's annual accounts for 2025 was approved. Additionally, the selection of Deloitte Accountants B.V. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The shareholders approved the appointment of three nominees as non-executive directors. Lastly, the extension of authorization for the board to acquire ordinary shares and depository receipts for ordinary shares in the company's capital was approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.